Who
Tran Nguyen
Chief Strategy Officer and CFO
Company insider
Files Form 4 as: Chief Strategy Officer and CFO, Prothena Corporation; Director, Rain Oncology; Director, Sierra Oncology; SVP and CFO, Pernix Sleep; VP and CFO, Metabasis Therapeutics.
In numbers
- Trades disclosed
- 118
- Buys
- 3
- Sells
- 16
- Bought
- $104K
- Sold
- $15.3M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 2 Mar 2009
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | —57,000 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code D | $488K57,000 at $8.56 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | —57,000 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code D | $488K57,000 at $8.56 | filing |
| 3 Mar 2026filed 5 Mar 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 28 Jul 2025filed 30 Jul 2025 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —107,500 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 26 Jan 2024filed 26 Jan 2024 | Rain Oncologyoption or derivative | SEC FORM 4 Code D | —13,890 | filing |
| 26 Jan 2024filed 26 Jan 2024 | Rain Oncologyoption or derivative | SEC FORM 4 Code D | —42,596 | filing |
| 26 Jan 2024filed 26 Jan 2024 | Rain Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 | filing |
| 26 Jan 2024filed 26 Jan 2024 | Rain Oncologyoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 9 Aug 2023filed 11 Aug 2023 | Rain Oncologyoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,000 at $0.00 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $1.3M45,000 at $29.81 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $1.1M50,000 at $22.85 | filing |
News
Prothena Corporation plc (PRTA) – What Are Analysts Saying About This Stock?PRTA · dailypolitical.com · 20 Oct 2026Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Company StockPRTA · dailypolitical.com · 15 Oct 2026Prothena (NASDAQ:PRTA) vs. Kyntra Bio (NASDAQ:KYNB) Financial ReviewPRTA · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Tran Nguyen; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.